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Summary
The teicoplanin acyltransferase (Atf) responsible for
N-acylation of the glucosamine moiety to create the
teicoplanin lipoglycopeptide scaffold has recently been
identified. Here we use that enzyme (tAtf) and the cog-
nate acyltransferase from the related A-40,926 bio-
synthetic cluster (aAtf) to evaluate specificity for gly-
copeptide scaffolds and for the acyl-CoA donor. In
addition to acylation of 2-aminoglucosyl glycopeptide
scaffolds with kcat values of 400–2000 min−1, both Atfs
transfer acyl groups to regioisomeric 6-aminogluco-
syl scaffolds and to glucosyl scaffolds at rates of 0.2–
0.5 min−1 to create variant lipoglycopeptides. Using
the teicoplanin glycosyltransferase tGtfA, tAtf, and
GtfD, a glycosyltransferase from the vancomycin pro-
ducer, it is possible to assemble a novel lipoglycopep-
tide with GlcNAc at -OH-Tyr6 and an N6-acyl-gluco-
saminyl-vancosamine at Phegly4. This study illustrates
the utility of chemo- and regioselective acyltransfer-
ases and glycosyltransferases to create novel lipo-
glycopeptides.
Introduction
The family of glycopeptide antibiotics is composed of
two subfamilies containing the clinically useful antibiot-
ics vancomycin and teicoplanin, respectively (Figure
1A). Each has an oxidatively crosslinked heptapeptide
scaffold constructed by nonribosomal peptide synthet-
ase assembly lines [1, 2], with sugars added by dedi-
cated glycosyltransferases (Gtfs) in post assembly line
tailorings (Figure 1B). Vancomycin has the disaccharide
L-vancosaminyl-1,2-D-glucose attached to the pheno-
lic hydroxyl of phenylglycine4 (Phegly4) of the scaffold
by the tandem actions of GtfE and GtfD [3, 4]. Tei-
coplanin is glycosylated with glucosamine on Phegly4
by tGtfB and is then N-acylated, capping the sugar
against further elongation. A separate Gtf, tGtfA, adds
N-acetylglucosamine (GlcNAc) to the β-OH of β-OH-
Tyr6, and finally, mannosylation occurs on residue 7
of the crosslinked heptapeptide by a mannosyltrans-
ferase. The teicoplanin family member A-40,926, also
shown in Figure 1A, differs from teicoplanin by posi-*Correspondence: christopher_walsh@hms.harvard.edutions of aromatic ring chlorination, an N-terminal methyl
group, the identity of the acyl chain, the absence of a
GlcNAc at the β-OH of scaffold residue 6, and a C6-
COOH oxidation state on the N-decanoyl-sugar resi-
due [5].
Perhaps the critical difference between teicoplanin,
a lipoglycopeptide, and vancomycin, a glycopeptide, is
the presence of the acyl chain which has been impli-
cated in its mechanism of antimicrobial activity [6].
Teicoplanin retains efficacy against type B strains of
vancomycin-resistant enterococci (VRE), while type A
strains of VRE are resistant to both teicoplanin and van-
comycin [7, 8]. The DNA sequences of biosynthetic
gene clusters for the vancomycin analog chloroeremo-
mycin [9], for teicoplanin [1, 2], and for the teicoplanin
analogs A-49,734 [10] and A-40,926 [5] have been re-
ported. This has enabled the identification and charac-
terization of tailoring Gtfs [3, 4] and more recently of the
tailoring acyltransferase (Atf) that adds the decanoyl
group to the glucosamine moiety of teicoplanin [1].
The A-40,926 cluster, but not the A-49,734 cluster,
has a homologous Atf [1, 5, 10], and we have now sub-
cloned that enzyme and purified it from E. coli. The two
enzymes share 67% sequence identity and 79% homol-
ogy. We report the characterization and substrate
specificities of both the teicoplanin Atf (tAtf) and the
A-40,926 Atf (aAtf) using several glycopeptide interme-
diates from both the vancomycin and teicoplanin sub-
families as scaffold substrates and a variety of acyl-
CoAs as acyl donor substrates. Remarkably, while the
normal substrate for the Atfs is a 2-aminoglucosyl-hep-
tapeptide scaffold, we find that a regioisomeric 6-amino-
glucosyl substrate on both the teicoplanin scaffold and
the vancomycin scaffold can be acylated at high pH.
kcat values of 0.2 min−1, down about three orders of
magnitude from 400–2000 min−1 determined here with
natural 2-aminoglucosyl scaffolds, still suffice for pre-
parative reactions. The N6-acylglucosaminyl scaffolds
can be further glycosylated, on the 2-OH, by the L-van-
cosaminyl transferase in the vancomycin maturation
pathway to create new lipoglycopeptide antibiotics.
This approach offers a chemoenzymatic route to this
class of compounds which shows good activity against
vancomycin-resistant strains [11–13].
Results
Cloning, Expression, and Purification
of Acyltransferases
Spencer and colleagues have recently identified the
acyltransferase in the teicoplanin biosynthetic gene
cluster, tei orf 11* (tAtf), and validated its activity after
purification from E. coli overproduction, although no ki-
netic or specificity characterization was reported [1].
They have also proposed that dbv orf 8 (aAtf) is the
corresponding aminosugar N-acyltransferase from
the A-40,926 producer [1]. In this paper we focus on
the kinetic characterization and substrate specificities
of these two enzymes. The two enzymes were PCR am-
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132Figure 1. Biosynthesis of Glycopeptide Antibiotics
(A) Chemical structures of three important glycopeptide and lipoglycopeptide antibiotics.
(B) The linear peptide backbone of the glycopeptide family of antibiotics is synthesized by NRPS machinery. The backbone is then acted on
by a number of tailoring enzymes including crosslinking oxidases, glycosyltransferases, acyltransferases, and methylases.plified from cosmid DNA provided to us by the Donadio [
vgroup at Vicuron Pharmaceuticals [2, 5], cloned into the
pET22b expression vector, and expressed in E. coli as o
oC-terminal His6-tagged proteins. The proteins were
purified by nickel chromatography to greater than 95% 1
gpurity based on SDS-PAGE analysis with a yield of 27




[The Atf enzymes acylate the sugar amino group of their
6corresponding 2-aminoglucosyl crosslinked heptapep-
etide scaffolds [1]. While there are slight variations be-
ctween the teicoplanin and A-40,926 backbones (i.e.,
cN-terminal methylation, differential aromatic chlorination,
othe absence of a GlcNAc at the β-OH of scaffold residue
6, and a C6-COOH oxidation state on the N-decanoyl-
sugar residue), we have chosen to use the teicoplanin I
oscaffold due to its availability [5]. The teicoplanin agly-
cone (AGT) and vancomycin aglycone (AGV) can be ob- a
ttained from teicoplanin or vancomycin through the acid
hydrolysis of the sugar groups in trifluoroacetic acid14, 15]. The aglycone can then be glycosylated with a
ariety of different sugar groups using the vancomycin
r chloroeremomycin glycosyltransferases as previ-
usly described [3, 4]. We enzymatically synthesized
0 mg of 2-aminoglucosyl AGT, 6-aminoglucosyl AGT,
lucosyl AGT, and 2-aminoglucosyl AGV, using the GtfE
nzyme, the corresponding UDP-sugar, and the hepta-
eptide aglycone scaffold as shown in Figure 2A.
Since GtfE has relaxed aglycone specificity [4], we
ere also able to glycosylate scaffolds where the amino
erminus was protected with the Alloc protecting group
6]. This allowed the synthesis of the N-decanoyl-
-aminoglucosyl AGT standard chemoenzymatically by
nzymatically glycosylating the protected aglycone,
hemically acylating the free amine on the 6-aminoglu-
osyl residue, and finally deprotecting the N terminus
f the heptapeptide.
nitial Kinetic Characterization
f the A-40,926 Acyltransferase
Atf was incubated with 2-aminoglucosyl AGT and oc-
anoyl-CoA, and the ensuing reaction was monitoredby HPLC. A representative A280 HPLC chromatogram is
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133Figure 2. Synthesis of Glycopeptides and UDP-6-Aminoglucose
(A) Chemoenzymatic synthesis of glycopeptides used in this study. (a) 500 M aglycone scaffold, 500 M UDP-sugar, 450 M GtfE. (b)
decanoyl succinimide (3 equiv.), Et3N, DMF, 16 hr, 57%. (c) Me2NH·BH3 (6 equiv), Pd(PPh3)4 (0.4 equiv), DMF, 30 min, 66%.
(B) Synthesis of UDP-6-aminoglucose used in the chemoenzymatic synthesis of 6-aminoglucosyl-containing scaffolds. (d) AcOH/H2O 4:1; (e)
Ac2O, pyridine, DMAP, 81% (two steps); (f) hydrazine acetate, DMF, 73%; (g) 1. dicyanoethyl diisopropylphosphoramidite, tetrazole, CH2Cl2;
2. mCPBA, CH2Cl2; 3. isomerization with BF3·OEt2, 69%; (h) NaOMe, MeOH; (i) H2, Pd-C, MeOH; (j) Teoc succinimide, 80% (three steps); (k)
UMP morpholidate, tetrazole, pyridine, 2 d; (l) Bu4NF, DMF/THF, 45% (two steps).shown in Figure 4E (bottom trace). The formation of a
new product with a retention time of 12 min was ob-
served, and the mass of the new peak determined by
LCMS ([M + H]+ = 1485.7) was consistent with the cal-
culated mass of N-octanoyl-2-aminoglucosyl AGT ([M
+ H]+ = 1485.4). To further verify the product of the acy-
lation reaction, we compared a reaction mixture con-
taining decanoyl-CoA to a previously reported authen-tic standard, N-decanoyl-2-aminoglucosyl AGT [6].
Coinjection of the reaction mixture and the standard
showed that the enzymatic product coeluted with the
chemically synthesized standard (data not shown).
Steady-state kinetic analysis shows that the kcat of aAtf
is 480 min−1, the Km of 2-aminoglucosyl AGT is 136 M,
and the K of octanoyl-CoA is 22 M at pH 7 (see Tablem
1). Parallel determination of the catalytic rate of tAtf re-
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134Table 1. aAtf Kinetic Parameters
Scaffold kcat (min−1) Km (M) kcat/ Km (min−1 M−1) pH
2-NH2-glucosyl AGT 480 136 3.53 7
2-NH2-glucosyl AGV 214 209 1.02 7
2-NH2-glucosyl AGT 592 18 32.9 9
6-NH2-glucosyl AGT 0.253 29 0.0087 9
Glucosyl AGT 0.574 42 0.0137 9
Parameters reported are the average of triplicate experiments.vealed a robust kcat of 1800 min−1, approximately 3-fold S
Tfaster than the A-40,926 enzyme.
f
sAcyl Chain Specificity
Teicoplanin and A-40,926 are naturally found as a mix- n
[ture of related compounds differing in the identities of
their acyl chains. The predominant form of A-40,926 a
shas an N-decanoyl modification, while there are five
major teicoplanin counterparts, all having between 10 2
aand 11 carbons on their acyl chains [1, 2, 5]. These
natural substrate tolerances led us to further explore t
pthe capabilities of these Atfs to act as combinatorial
chemoenzymatic tools to generate libraries of novel li- c
Tpoglycopeptides. The specificities of both Atfs were
tested using the series of acyl-CoA substrates shown 2
tin Figure 3A. With the exception of hexynoyl-CoA and
biphenoyl-CoA, which were synthesized using the 4
pgeneral fatty acid/coenzyme A condensation strategy
previously reported [16], all of these substrates were 2
tcommercially available.
The results of the acyl chain specificity analysis are A
oshown in Figures 3B and 3C. Both enzymes had a pref-
erence for long-chain acyl-CoAs. While trace amounts o
bof product formation were observed using isobuty-
ryl-, β-hydroxybutyryl-, crotonoyl-, and benzoyl-CoA by
LCMS, the turnover was too slow to be quantified by S
IHPLC. Biphenoyl-CoA was not a substrate for either
enzyme. The best substrate for aAtf was the C12 acyl a
tchain of lauroyl-CoA, while the best substrate for tAtf
was decanoyl-CoA. In general the most robust sub- t
nstrates were acyl chains containing between 6 and 14
carbons. Across the acyl chain range, tAtf maintained a
6a higher activity than aAtf. -aminoglucosyl AGT was synthesized and tested. When
Figure 3. Acyl-CoA Specificity of aAtf and tAtf
(A) Chemical structures of acyl-CoAs used in this study.
(B and C) V/E comparison of the utilization of various acyl-CoA substrates using the aAtf and tAtf enzymes. The assay conditions are
described in the Experimental Procedures.caffold Specificity
he vancomycin and chloroeremomycin glycosyltrans-
erases will accept either a vancomycin or a teicoplanin
caffold, allowing the chemoenzymatic synthesis of
ovel glycopeptides with modified sugar substituents
3, 4]. To ascertain whether the acyltransferases, which
ct on teicoplanin-type scaffolds, might share a similar
caffold tolerance, the ability of the Atfs to acylate
-aminoglucosyl AGV was evaluated. Indeed, both aAtf
nd tAtf accept vancomycin scaffolds. Kinetic charac-
erization of aAtf with 2-aminoglucosyl AGV and com-
arison to 2-aminoglucosyl AGT shows that both ac-
eptor substrates are accepted nearly equally (Table 1).
he kcat for the vancomycin scaffold (214 min−1) is
-fold lower than that of the teicoplanin scaffold, and
he Km (209 M) is about 2-fold higher, resulting in a
-fold drop in catalytic efficiency. Although the com-
lete kinetic characterization of the tAtf enzyme with
-aminoglucosyl AGV was not performed, we qualita-
ively observed that tAtf could accept 2-aminoglucosyl
GV as a substrate as well (data not shown). The ability
f these acyltransferases to acylate different scaffolds
pens the door to generating novel lipoglycopeptides
ased on the vancomycin scaffold structure.
ugar Specificity
n addition to scaffold and acyl chain specificities, the
bility of the acyltransferase enzymes to recognize al-
ernate sugars was examined. In the physiologic set-
ing, the Atf enzymes recognize the nucleophilic amino
itrogen at the 2 position of the glucosyl ring. To see if
cylation would proceed at other positions on the ring,
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135this regioisomeric aminohexosyl scaffold was incu-
bated with either Atf, two products could be detected
(Figure 4E, middle trace), with one of the products in
excess over the other.
LCMS analysis, as summarized in Table 2, provides
insight into the identities of the two products. While the
mass of each product is consistent with a single acyla-
tion of the scaffold, the major product flies as a doubly
charged ion while the minor product flies only as a sin-
gly charged ion. Teicoplanin aglycone flies only as the
singly charged ion (presumably ionization of the N-ter-
minal amine). Both 2-aminoglucosyl- and 6-aminoglu-
cosyl AGT fly as doubly charged ions (presumably both
the N-terminal amine and the sugar amine are ionized).
N-octanoyl-2-aminoglucosyl AGT flies only as the
singly charged ion (the acylated sugar amine can no
longer be ionized, and only the N-terminal amine re-
mains ionizable). Since the major product of the acyla-
tion with 6-aminoglucosyl AGT flies as a doubly
charged ion, we can deduce that the sugar amine re-
mains unmodified, and acylation must have occurredFigure 4. pH Dependence on aAtf Activity with Alternate Substrates
(A) pH dependence on 2-aminoglucosyl AGT utilization. Data were fit to a single ionization resulting in an estimated pKa of 6.7.
(B) pH dependence on glucosyl AGT utilization.
(C) pH dependence on 6-aminoglucosyl AGT utilization.
(D) Plot depicting how the ratio of products changes with increasing pH for reactions containing glucosyl AGT or 6-aminoglucosyl AGT.
(E) Representative A280 HPLC traces showing the substrates and products from reactions where 2-aminoglucosyl-, 6-aminoglucosyl-, and
glucosyl AGT served as substrates at pH 7.0. The y axis is linear and is in units of absorbance.product, presumably the 2-O-decanoyl-glucosyl AGT,
Table 2. LCMS Results for Heptapeptide Acylation with Octanoyl-CoA
Theor. Exp. Major Exp. Minor
Scaffold Theor. Exp. z Product Product z Product z
2-NH2-glucosyl AGT 1359.3 1359.8 +2 1485.4 1485.7 +1 — —
2-NH2-glusocyl AGV 1304.4 1305.6 +2 1430.5 1431.0 +1 — —
6-NH2-glucosyl AGT 1359.3 1359.6 +2 1485.4 1486.6 +2 1486.2 +1
Glucosyl AGT 1360.3 1361.0 +1 1486.4 1487.1 +1 — —at an alternate site, most likely the 2-OH position of the
sugar, given the natural regiospecificity of the acyl-
transferase for the C2 substituent of the hexose. Since
the minor product flies as the singly charged ion, we
presume that the sugar amine has been acylated and
this is the N6 octanoyl product, a novel site of acylation.
A chemically synthesized N-decanoyl-6-aminogluco-
syl AGT standard was used for HPLC and LCMS
comparison to the reaction products resulting from an
incubation of aAtf with 6-aminoglucosyl AGT and dec-
anoyl-CoA. HPLC coinjection verified that the chemi-
cally synthesized standard coeluted with the minor re-
action product, and LCMS of the synthetic standard
shows the singly charged ion (data not shown).
The ability of the acyltransferases to acylate sugar
hydroxyls was confirmed by changing the sugar iden-
tity to glucose, thereby removing the amine altogether.
Thus, glucosyl AGT could be utilized as an acylation
substrate, and the formation of a new product could
be detected by HPLC (Figure 4E, top trace). This new
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136flies as a singly charged ion by LCMS analysis as ex- i
upected, since there is only one amine available on the
molecule for ionization. In order to provide NMR evi- c
tdence for the position of acylation on glucosyl scaf-
folds, we choose to acylate the glucosyl vancomycin N
uscaffold. We isolated 5 mg of the major acylated pro-
duct by HPLC. The presence of a 2-O-acyl group was N
Tconfirmed by its 1H NMR spectrum (500 MHz, d6-
DMSO). The signal for the H-2 proton (δ = 4.85) of the G
aglucose residue (assigned based on the COSY cross
peaks) showed a distinct shift compared to the H-2 sig- t
unal obtained for glucosyl vancomycin (δ = 3.55), charac-
teristic for an acyl group attached to this position. No L
mshift was observed at the other positions of the glu-
cose ring.
To further explore this 2-OH and 6-NH2 activity, we D
determined the pH optimum of aAtf using 2-aminoglu-
cosyl-, 6-aminoglucosyl-, and glucosyl AGT. With the N
natural substrate (2-aminoglucosyl AGT), the pH de- s
pendence leveled off at pH 8 (Figure 4A). Fitting the pH d
dependence to a single ionization resulted in a pKa of c
6.7. The pH dependence of both the glucosyl- and t
6-aminoglucosyl AGT scaffolds shows an increasing m
rate with pH up to the pH of enzyme stability, pH 10 c
(Figures 4B and 4C). Interestingly, at higher pH values, e
a second minor monoacylated product could be seen c
forming in the glucosyl AGT reactions similar to the se- a
cond minor product observed in the 6-aminoglucosyl s
AGT reactions. Due to the presence of two products, o
the velocity determined in these pH dependence ex-
periments was taken as the sum of the rates of forma- a
tion of each individual product. Figure 4D shows how t
the ratio between the two products changes as a func- a
tion of pH for both substrates; at lower pH’s acylation f
at C2 predominates, while the amount of C6 acylation d
increases at higher pH’s. 2
While the activity was highest at pH 10, the formation A
of the minor product could be minimized by reducing t
the pH, and kinetic parameters for these substrates t
were determined at pH 9 (summarized in Table 1). The d
Km for 2-aminoglucosyl AGT was reduced about one (
order of magnitude to 18 M at pH 9 as compared to
pH 7, resulting in a higher catalytic efficiency. The a
6-aminoglucosyl- (29 M) and glucosyl (42 M) AGT e
scaffolds had similar Km values as the natural sub- l
strate, while their kcat values were reduced about 1000- i
fold (0.253 min−1 and 0.574 min−1, respectively). a
These results highlight two important findings: first, s
that tAtf and aAtf can catalyze the acylation of sugar w
hydroxyl groups, and second, that they can also ac- E
ylate amines at position C6 of the glucosyl ring. Al- c
though both activities occur at significantly reduced s
rates, they can be preparatively useful in the chemoen- p
zymatic synthesis of novel lipoglycopeptides. c
b
Synthesis of Novel Lipoglycopeptides
To demonstrate the utility of the glycosyltransferase m
uand acyltransferase enzymes from the glycopeptide
biosynthetic machinery to generate novel lipoglyco- t
tpeptides, two lipoglycopeptide derivatives were gener-
ated as summarized in Figure 5. The first, compound t
16, is a teicoplanin analog that contains an acylated
vancomycin disaccharide chain at Phegly and is miss- f4ng its N-acetylglucosamine sugar at β-OH-Tyr6. This
tilized the 6-aminoglucosyl AGT scaffold with aAtf-
atalyzed enzymatic acylation of the 6-amino group on
he sugar with decanoyl-CoA. Then, GtfD formed the
-acylated disaccharide by adding L-vancosamine (Fig-
re 5A). In the second derivative, compound 19, the
-acetylglucosamine sugar was added to the β-OH-
yr6 hydroxyl of 6-aminoglucosyl AGT, using tGtfA (the
tfA analog from the teicoplanin cluster). Then aAtf-
nd GtfD-mediated steps were employed sequentially
o complete the three tailoring enzyme sequence (Fig-
re 5A). All reactions were monitored by HPLC and by
CMS. Representative HPLC traces showing the for-
ation of compound 16 are shown in Figure 5B.
iscussion
atural products generated on nonribosomal peptide
ynthetase multimodular assembly lines commonly un-
ergo a series of post assembly line tailoring reactions
atalyzed by dedicated tailoring enzymes encoded in
he biosynthetic genes clusters [17]. These enzymatic
aturation steps may be crucial for the gain of biologi-
al activity, as typified by glycosylations of deoxy-
rythronolide B on the way to the antibiotic erythromy-
in and by the tandem oxidative crosslinkings of the
cyclic heptapeptide to generate the rigid aglycone
caffolds for vancomycin and teicoplanin family antibi-
tics.
In toto, vancomycin undergoes three types of post
ssembly line enzymatic tailorings: Leu1-N-methyla-
ion, the oxidative crosslinking of side chains 2–4, 4–6,
nd 5–7, and two glycosylations. Teicoplanin undergoes
our oxidative crosslinkings, including side chains of resi-
ues 1–3, three glycosylations, and one acylation of the
-aminoglucosyl moiety. The teicoplanin family member
-40,926 undergoes all of the teicoplanin modifica-
ions, except β-OH-Tyr6 glycosylation, plus two addi-
ional ones: Leu1-N-methylation and 2-aminoglucose
ouble oxidation at C6 to the COOH oxidation state
Figure 1).
In this study we have focused on the acyltransfer-
ses from the teicoplanin and A-40,926 clusters, the
nzymes responsible for conversion of glycopeptide to
ipoglycopeptide scaffolds. Sequencing of the clusters
dentified likely candidates for the Atfs [1, 5], and the
ctivity of tAtf was validated experimentally by the
tudies of Spencer and colleagues that showed that,
hen heterologously expressed in and purified from
. coli, tAtf was active for acylation of the 2-aminoglu-
osyl moiety both on the crosslinked heptapeptide
caffold and as UDP-2-aminoglucose [1]. Here we have
erformed initial kinetic characterization of both the tei-
oplanin tAtf and the homologous A-40,926 aAtf for
oth scaffold and acyl-CoA substrates.
Both Atfs are robust catalysts, with kcat values of 400
in−1 and 2000 min−1 for aAtf and tAtf, respectively,
sing the substrate pair 2-aminoglucosyl AGT and oc-
anoyl-CoA at pH 7. Both Atfs show reasonable utiliza-
ion of C6-C14 acyl-CoA substrates but very low activi-
ies with short chain and aromatic acyl-CoAs.
Analysis of glycosyl-crosslinked heptapeptide scaf-
olds as substrates confirms that the 2-aminoglucosyl
Characterization of Glycopeptide Acyltransferases
137Figure 5. Chemoenzymatic Synthesis of Novel Lipoglycopeptides
(A) Schematic showing the synthetic strategy toward compounds 16 and 19 starting from 6-aminoglucosyl AGT.
(B) A280 HPLC traces showing the successive conversion of 6 to 15 and of 15 to 16 using aAtf and GtfD, respectively. The peak labeled “a”
corresponds to 2-O-decanoyl-6-aminoglucosyl teicoplanin, while the peak labeled “b” corresponds to a doubly acylated product. Reaction
conditions are described in the Experimental Procedures.moiety is the preferred nucleophilic cosubstrate. As the
pH is raised, detectable activity in the HPLC/MS assay
is observed with glucosyl AGT for monoacylation with
octanoyl-CoA as donor. Assuming the regiochemistry
is maintained, this would represent a substitution of the
2-NH2 group by the 2-OH group of the sugar. We iso-
lated 5 mg of acylated glucosyl vancomycin scaffold,
and NMR analysis shows a distinctive shift of the H-2
proton of the glucose ring confirming the site of acy-
lation. The pKa of the -OH versus -NH3+ is about 5 units
higher for generation of the 2-O−, consistent with the
monotonic rise of kcat for the glucosyl acceptor sub-
strate, while the 2-NH2-substrate shows a plateau
above pH 8.
When 6-aminoglucosyl AGT was evaluated as a sub-
strate, a pH profile and kcat comparable to the glucosyl-
scaffold was observed. In this case two monoacylated
products are detected (Figure 4E, middle trace). One of
these is likely to be the 2-O-octanoyl-6-NH2-glucosyl
product, which appears to be the major kinetic product,
while the other is likely to be the N6-octanoyl-glucosyl
product. We have verified the location of this N6 acyla-
tion by comparing an authentic standard made chemi-
cally to the enzymatic product by HPLC and LCMS
analysis. This apparent relaxation of the regioselectivity
of the Atfs might be useful in the chemoenzymatic syn-
thesis of glycopeptide derivatives where acyl chains
can be appended to either the 2 or the 6 position of the
glucosyl ring.
In particular, if the 2-OH of the 6-aminoglucosyl moi-
ety is still free, one might expect this should enable
further modification of the glucosyl moiety by vanco-
samine or epivancosamine by GtfD or GtfC, respec-
tively. To that end the tandem incubations depicted in
Figure 5 were conducted where the 6-aminoglucosyl
AGT scaffold was subjected to Atf action, followed by
GtfD and TDP-L-vancosamine. These were done in par-
allel following glycosylation of the β-OH of β-OH-Tyr6with GlcNAc by the teicoplanin tGtfA glycosyltransfer-
ase. In both cases decanoyl transfer was followed by
vancosaminyl transfer to generate compounds 16 and
19, containing the N6-decanoyl-glucosyl-2-L-vancosami-
nyl substituent. These are lipoglycopeptides with the
vancomycin-type disaccharide grafted on the teicoplanin
scaffold, and the decanoyl side chain placed, not at N2,
but at N6. Compound 16 is an analog of a vancomycin
derivative previously synthesized chemically [13], while
19 has the three-sugar (disaccharide at residue four,
monosaccharide at residue six) pattern characteristic
of chloroeremomycin. The decanoyl-N6 regiochemistry
is intriguing and distinct from the N-chlorobiphenyl
substitution on the amino group of the vancosaminyl
sugar found in the clinical candidate oritavancin that is
highly active against vancomycin-resistant enterococci.
Lipoglycopeptides are of interest, given that many of
these compounds show improved activity against van-
comycin-resistant bacteria [6, 11–13] and that two of
the second-generation glycopeptides in clinical de-
velopment, dalbavancin and oritavancin [18, 19], con-
tain N-decanoyl and N-aryl substituents, respectively.
The ability to decorate teicoplanin and vancomycin
aglycone scaffolds with combinations of acyl-CoA and
NDP-L- and NDP-D-hexoses (deoxy- and amino-) via
action of Atfs and Gtfs should provide routes to new
variants in the lipoglycopeptide class.
Significance
The vancomycin and teicoplanin group of natural pro-
duct antibiotics share related crosslinked heptapep-
tide scaffolds that are produced by nonribosomal
peptide synthetases and then become glycosylated
by dedicated tailoring enzymes. One distinction be-
tween teicoplanin and vancomycin is that teicoplanin
is a lipoglycopeptide, bearing a long-chain acyl group
on the 2-aminoglucosyl moiety. We have now charac-
Chemistry & Biology
138Cterized the recently discovered acyltransferase (Atf)
Tfrom the teicoplanin biosynthetic cluster and a ho-
tmologous Atf from the A-40,926 cluster with regard
C
to specificity for acyl-CoA donors and glucosyl-hep- 3
tapeptide nucleophilic acceptors. The ability of the p
aAtfs to use both vancomycin and teicoplanin scaf-
qfolds, with glucosyl, 2-aminoglucosyl, and 6-amino-
cglucosyl acceptors, defines specificity parameters for
ucreation of novel lipoglycopeptide variants. In partic-
ular, the ability of the Atfs to make N6-long-chain acyl Cderivatives of 6-aminoglucosyl scaffolds, followed by V
regiospecific Gtfs, demonstrates that tandem Atf and w







All chemicals were purchased from Aldrich or Sigma and used b
without further purification. Solvents were reagent grade and were u
further dried when necessary. Analytical thin-layer chromatography r
was performed on aluminum plates precoated with silica gel (250 H
m, Sigma), with detection by UV and/or spraying with H2SO4 m
(50%). Flash chromatography was carried out on silica gel (60 Å, n
32–63 m) purchased from Sorbent Technologies. NMR spectra p
were recorded on Varian Mercury 300 MHz and Inova 400 and 500 U
MHz spectrometers. Mass spectra (ESI) were obtained at the Mass g
Spectroscopy Facility at the Department of Chemistry, Princeton p
University, or with a Shimadzu QP8000 LCMS. d
f
g
aAtf and tAtf Plasmid Construction T
The genes responsible for encoding aAtf and tAtf, dbv orf 8 and tei a
orf 11*, respectively, were PCR amplified from cosmids provided (
by the Donadio group at Vicuron Pharmaceuticals [2, 5] using the
following primer pairs: 5#-GGAATTCCATATGGATGCTGAGAGCGTG
1CGCAGGCAGC-3# and 5#-CCCAAGCTTGGGCAGCTCGATGCGGC
ACGCTCC-3# for dbv orf 8 and 5#-GGAATTCCATATGGATCCCGA
fGACCGTACGCATCG-3# and 5#-CCGCTCGAGCGGCAGCTTGAAG
sCCCGTCCGCAT-3# for tei orf 11*, where the restriction sites for
cNdeI, HindIII, and XhoI are underlined. The PCR products were
pcloned into pET22b expression vectors generating the pET-22b-
maAtf-His6 and pET-22b-tAtf-His6 plasmids, and the open reading tframes were confirmed by DNA sequencing prior to transformation
sinto E. coli BL21DE3.
(
d
aHeterologous Expression and Purification of aAtf and tAtf
(E. coli BL21DE3 transformants were inoculated into 10 ml of LB
Hmedium containing 100 g/ml ampicillin and were grown at 37°C
3overnight. Each overnight culture was added to 1 liter of LB con-
2taining 100 g/ml ampicillin, and the cultures were incubated at
37°C until an OD600 of 0.6 was reached. The cultures were cooled
to 15°C and were induced with 0.3 mM IPTG for 20 hr. Bacteria D
were harvested by centrifugation, and the cell pellets were resus-
pended in buffer A (25 mM MOPS [pH 7.0], 100 mM NaCl, and 5 A
tmM imidazole). Bacteria were lysed in a French press (3 × 15,000
psi), and cell debris was removed by centrifugation (14,000 × g, 20 m
mmin). Cell lysates were mixed with 1 ml of preequilibrated Ni-NTA
resin at 4°C for 1 hr before loading into a column. The column was m
ewashed with 10 column volumes of buffer A followed by 10 column
volumes of buffer A containing 30 mM imidazole. The proteins were (
ieluted with buffer A containing 200 mM imidazole, and fractions
were analyzed by 12% SDS-PAGE. The desired fractions were s
4pooled, transferred to a Slide-A-Lyzer dialysis cassette (10 kDa MW
cutoff), and dialyzed twice against 2 liters of dialysis buffer (50 mM (
pMOPS [pH 7.0], 100 mM NaCl, and 10% (v/v) glycerol). The protein
concentrations were determined from their theoretical extinction a
ccoefficients at 280 nM (67,380 M−1 cm−1 for aAtf and 73,910 M−1
cm−1 for tAtf) [20, 21]. The proteins were flash frozen at 280 M in m
rliquid nitrogen and stored at −80°C.loning, Expression, and Purification of tGtfA
he tgtfA gene was PCR amplified from the plasmid pAT9 using
he following primer pair: 5#-AAAAAACATATGCGCGTGCTGTTTT
GTCCTAC-3# and 5#-AAAAAAAAGCTTCGCGGGAACCGACGATCT-
#, in which the NdeI and HindIII sites are underlined. The PCR
roduct was cloned into the pET22b expression vector (Novagen),
nd the open reading frame of tgtfA was confirmed by DNA se-
uencing before it was transformed into BL21(DE3)-competent
ells (Invitrogen). The tGtfA protein was expressed and purified
sing a previously described method [22].
hemoenzymatic Synthesis of Glycopeptide Scaffolds
ancomycin aglycone (AGV) 1 and teicoplanin aglycone (AGT) 3
ere synthesized as previously described [14, 15]. These agly-
ones were then enzymatically glycosylated [3] with UDP-glucose,
DP-2-aminoglucose, or UDP-6-aminoglucose using the vancomy-
in biosynthetic glycosyltransferase GtfE to yield the monoglycosy-
ated scaffolds 2 and 4–6 as shown in Figure 2A. The reaction con-
itions were as follows: 75 mM Tricine (pH 9.0), 8 mM MgCl2, 2.5
M TCEP, 1 mg/mL BSA, 10% (v/v) DMSO, 500 M UDP-sugar,
00 M aglycone, and 450 M GtfE. The reactions were monitored
y HPLC, and additional aliquots of GtfE were added twice daily
ntil the reaction proceeded to 50% completion (up to 3 days). The
esulting monoglycosylated scaffolds were purified by preparative
PLC (Vydac C18 column, 0%–30% acetonitrile, 0.1% TFA in 25
in) and were verified by LCMS. For the synthesis of 9, the N termi-
us of 3 was Alloc protected to generate compound 7 as described
reviously [6]. The protected aglycone was then glycosylated with
DP-6-aminoglucose to generate glycopeptide 8. Alloc-protected
lycopeptide 8 was then acylated with a decanoyl chain and de-
rotected to generate 9 as described for the corresponding 2-NH-
ecanoyl analog previously synthesized [6]. The NDP-sugars used
or the enzymatic glycosylations were obtained as follows: UDP-
lucose was commercially available, UDP-2-aminoglucose [23] and
DP-L-vancosamine [24] were synthesized as previously described,




uranose (10; 10.0 g, 40.7 mmol) [25] in AcOH/H2O (4:1, 300 ml) was
tirred at 80°C for 16 hr. The resulting solution was evaporated,
oevaporated with toluene (3×), and the residue was dissolved in
yridine (100 ml). After the addition of Ac2O (50 ml) and DMAP (500
g), the solution was stirred at RT for 8 hr. Following evaporation,
he residue was dissolved in CH2Cl2 and washed with 1 N HCl,
atd. aq. NaHCO3, and brine. The organic phase was dried
MgSO4), evaporated, and coevaporated with toluene, and the resi-
ue was crystallized from petroleum ether/AcOEt to give the tetra-
cetate 11 (12.3 g, 81%) as a 1:1 mixture of anomers. 1H NMR
CDCl3, 300 MHz): δ 6.34 (d, J1,2 = 3.6 Hz, H-1α), 5.71 (d, J1,2 = 8.2
z, H-1β), 5.45, 5.34, 5.15–5.03 (t, t, m, H-2, H-3, H-4), 4.12–4.02,
.84–3.76 (2 m, H-5α, H-5β), 3.42–3.25 (m, 6-H2), 2.17, 2.11, 2.05,
.04, 2.02, 2.01 (OAc).
icyanoethyl (2,3,4-Tri-O-Acetyl-6-Azido-6-Deoxy-
-D-Glucopyranosyl) Phosphate (12)
solution of tetraacetate 11 (6.0 g, 16.1 mmol) and hydrazine ace-
ate (1.93 g, 20.9 mmol) in DMF (18 ml) was stirred at 65°C for 30
in. After cooling to RT, the solution was diluted with EtOAc (500
l) and washed with H2O (2 × 150 ml), satd. aq. NaHCO3 (2 × 150
l), and brine (150 ml), and the aqueous phases were back-
xtracted with EtOAc. The combined organic phases were dried
MgSO4), evaporated, and purified by flash chromatography on sil-
ca gel (petroleum ether/EtOAc 2:1) to give the lactol as a colorless
yrup (3.9 g, 73%). The lactol (3.3 g, 10 mmol) and tetrazole (2.8 g,
0 mmol) were coevaporated with toluene (3×), dissolved in CH2Cl2
80 ml), and cooled to −5°C. A solution of dicyanoethyl diisopropyl-
hosphoramidite (5.42 g, 20 mmol) in CH2Cl2 (80 ml) was then
dded, and the temperature was allowed to reach RT over the
ourse of 1.5 hr. The solution was cooled to −40°C, a solution of
CPBA (3.5 g, 20 mmol) in CH2Cl2 (80 ml) was added, and the
eaction mixture was warmed to RT over 1 hr. After the addition of
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139aq. Na2SO3 (10%, 100 ml), the mixture was extracted with CH2Cl2,
and the organic phase was washed with satd. aq. NaHCO3 (2×)
and brine. The organic phase was dried (MgSO4), evaporated, and
purified by flash chromatography on silica gel (petroleum ether/
EtOAc 1:9) to give the phosphate 12 (4.6 g; Rf = 0.1, petroleum
ether/EtOAc 1:4) as a mixture of anomers (α/β = 3:1 according to
1H NMR). Removal of the undesired β-anomer using silica gel chro-
matography was unsuccessful; therefore, the anomeric mixture
was isomerized to the more stable α-anomer using a catalytic
amount of BF3·OEt2 in CH2Cl2. After 1.5 hr, the reaction was neu-
tralized by adding a few drops of Et3N, washed with brine, dried
(MgSO4), evaporated, and purified by flash chromatography on sil-
ica gel (petroleum ether/EtOAc 1:6, then pure EtOAc) to give the
α-anomer of phosphate 12 (3.6 g, 69%) as a colorless syrup. 1H
NMR (CDCl3, 300 MHz): δ 5.92 (dd, 1 H, J1,2 = 3.3, J1,P = 6.6 Hz, H-1),
5.46, 5.09 (2 t, each 1 H, J = 10.1 Hz, H-3, H-4), 5.03–4.98 (m, 1 H,
H-2), 4.40–4.30 (m, 4 H, OCH2), 4.22–4.16 (m, 1 H, 5-H), 3.45 (dd, 1
H, J5,6a = 2.2, J6,6 = 13.5 Hz, H-6a), 3.37 (dd, 1 H, J5,6b = 5.9, J6,6 =
13.5 Hz, H-6b), 2.88–2.80 (m, 4 H, CH2CN), 2.09, 2.05, 2.02 (3 s,
each 3 H, 3 OAc); MS (ESI) for C18H24N5O11P (517.38): 516 [M–H]−.
6-(2-Trimethylsilylethyloxycarbonyl)-Amino-6-Deoxy--D-
Glucopyranosyl Phosphate (13)
To a solution of phosphate 12 (725 mg, 1.4 mmol) in MeOH (20 ml)
was added NaOMe (7 ml, 0.5 M in MeOH, 3.5 mmol), and the mix-
ture was stirred at 55°C for 30 min. After evaporation of the solvent,
the residue was dissolved in H2O (30 ml). The solution was neutral-
ized with Amberlite IRC50, filtered, and extracted with Et2O (20 ml).
Pd-C (400 mg) was then added, and the suspension was stirred
under H2 (1 atm) for 3 hr, filtered, and evaporated to a final volume
of ca. 10 ml. After the addition of Teoc succinimide (540 mg, 2.1
mmol) and Et3N (0.5 ml), the mixture was stirred for 16 hr and evap-
orated. The residue was purified by flash chromatography on silica
gel (CH2Cl2/MeOH/H2O/Et3N 16:4:0.5:0.3, then 16:8:2:0.5) to afford
phosphate 13 (630 mg, 80%; Rf = 0.2, CH2Cl2/MeOH/H2O/Et3N
16:4:0.5:0.3) as the triethylammonium salt (1.6 eq.). 1H NMR (CD3OD,
400 MHz): δ 5.47 (dd, 1 H, J1,2 = 3.5, J1,P = 6.9 Hz, H-1), 4.13–4.05
(m, 2 H, OCH2), 3.85–3.78 (m, 1 H, H-5), 3.64 (t, 1 H, J2,3 = J3,4 = 9.6
Hz, H-3), 3.52 (d, 1 H, J6,6 = 12.3 Hz, H-6a), 3.36–3.32 (m, 1 H, H-2),
3.22–3.12 (m, 2 H, H-4, H-6b), 1.27 (t, 2 H, CH2 SiMe3), 0.02 (s, 9 H,




Phosphate 13 (590 mg, 1.05 mmol) and trioctylamine (0.47 ml, 1.05
mmol) were coevaporated with pyridine (3×). UMP morpholidate
(1.15 g, 1.67 mmol) was added, and the mixture was coevaporated
with pyridine (3×). The residue was dissolved in pyridine (8 ml),
tetrazole (250 mg, 3.2 mmol) was added, and the mixture was
stirred for 2 days. Following evaporation, the residue was dissolved
in H2O containing 0.1% NH4HCO3 (18 ml), extracted with Et2O, and
purified by preparative reversed-phase HPLC to give the protected
UDP derivative (420 mg, 56%). This compound was dissolved in
DMF (5 ml), Bu4NF (1 M in THF, 5 ml) was added, and the solution
was stirred for 16 hr. After removal of the solvents, the residue was
dissolved in H2O containing 0.1% NH4HCO3 (10 ml), filtered, and
purified by preparative reversed-phase HPLC to afford the UDP
sugar 14 (265 mg, 80%) as its ammonium salt. 1H NMR (D2O, 400
MHz): δ 7.98 (d, 1 H, J = 8.1 Hz, uridine Cnb-H), 5.99–5.95 (m, 2 H,
uridine Cnb-H, H-1 [ribose]), 5.63 (dd, 1 H, J1,2 = 3.5, J1,P = 6.9 Hz,
Hnb-1), 4.40–4.20 (m, 5 H, H-2, H-3, H-4, H-5 [ribose]), 4.12 (dt, 1
H, J4,5 = J5,6b = 9.9, J5,6a = 2.7 Hz, H-5), 3.78 (t, 1 H, J2,3 = J3,4 = 9.8
Hz, H-3), 3.60 (dt, 1 H, J1,2 = J2,P = 3.5, J2,3 = 9.8 Hz), 3.48 (dd, 1 H,
J5,6 = 2.7, J6,6 = 13.2 Hz, H-6a), 3.36 (t, 1 H, J3,4 = 9.8, J4,5 = 9.9 Hz,
H-4), 3.11 (dd, 1 H, J5,6b = 9.9, J6,6 = 13.2 Hz, H-6b); 31P NMR (D2O,
162 MHz): δ −10.4, −12.1; MS (ESI) for C15H25N3O16P2 (565.3): 564
[M–H]−.
Initial Kinetic Characterization of aAtf
Octanoyl-CoA (25–200 M) and either 2-aminoglucosyl AGT (70–
700 M) or 2-aminoglucosyl AGV (90–900 M) were incubated at
37°C with 40 nM aAtf in 25 µl of reaction buffer (75 mM Tris [pH 7.0],8 mM MgCl2, 2.5 mM TCEP, 1 mg/ml BSA, and 10% [v/v] DMSO) for
2 min, after which the reactions were quenched by the addition of
50 µl methanol. The quenched reactions were centrifuged for 2 min
at 13,000 rpm, and 20 µl of the supernatant was injected into a
Vydac analytic C18 HPLC column. Reaction mixtures were eluted
using a gradient from 10% to 75% acetonitrile and 0.1% TFA in
20 min, and products were monitored at 280 nm. Negative control
reactions were performed for all assays where enzyme was left out
to verify there was no detectable nonenzymatic reaction. Molecular
weights of substrates and products were verified by LCMS. The
peaks for the acylated products and the unacylated substrates
were integrated, and the product concentration was deduced from
its percentage of the total peak area. The resulting initial velocity
data were fit to the Michaelis-Menten equation to generate the ki-
netic parameters kcat and Km. Full kinetic characterization of tAtf
was not performed, and instead an estimate of the kcat for tAtf was
determined by incubating 40 nM tAtf with saturating amounts of
both substrates (700 M 2-aminoglucosyl AGT and 500 M octa-
noyl-CoA) using the assay conditions outlined above allowing di-
rect comparison to aAtf.
Atf Acyl Chain Specificity
aAtf and tAtf were incubated with 100 M of various acyl-CoA sub-
strates (see Figure 3A) and 100 M 2-aminoglucosyl AGT using the
assay conditions outlined above. The enzyme concentration varied
between 50 nM and 4 M depending on the reactivity of each acyl-
CoA substrate. Initial velocities were determined for each acyl-CoA
with both Atfs in triplicate. The resulting velocity was normalized
by the enzyme concentration to generate V/E, which was plotted
for each acyl-CoA.
Atf Sugar Specificity
The kinetic parameters kcat and Km were determined for the tei-
coplanin scaffold containing one of three different sugars (2-amino-
glucose, 6-aminoglucose, or glucose) at pH 9.0. aAtf was incubated
with 50–2000 M scaffold and 1 mM octanoyl-CoA at 37°C in 25 µl
of reaction buffer (75 mM Tris [pH 9.0], 8 mM MgCl2, 2.5 mM TCEP,
1 mg/ml BSA, and 10% [v/v] DMSO). In the 2-aminoglucosyl AGT
reactions, 40 nM aAtf was used with 2 min reaction times, while in
the 6-aminoglucosyl AGT and glucosyl AGT reactions, 5 M aAtf
was used with 10 min reaction times. The reactions were quenched
and HPLC analyzed as described above.
To identify the sites of acylation for these substrates, comparison
of reaction products to known chemical standards or NMR analysis
was performed. 2-N-decanoyl-glucosyl AGT and 6-N-decanoyl-glu-
cosyl AGT were coinjected with the corresponding reaction mix-
tures to verify acylation at the C2 or C6 amine, respectively. Since
an authentic standard for the acylation of a glucosyl scaffold was
unavailable, 5 mg of the major reaction product between glucosyl
vancomycin and decanoyl-CoA was purified by HPLC, and the 1H
NMR spectrum was determined (500 MHz, d6-DMSO). The spectrum
of the reaction product was compared to that of glucosyl vancom-
cyin showing a distinctive shift in the H-2 proton of the glucose
residue while the other protons remained unaffected.
pH Dependence of aAtf Activity
The pH dependence of the aAtf reaction was determined using
2-aminoglucosyl-, 6-aminoglucosyl-, or glucosyl AGT as acceptor
substrates over a pH range from 6.5 to 10 at every 0.5 pH unit.
Reactions were performed with 200 M scaffold, 500 M octanoyl-
CoA, at 37°C in 25 µl of reaction buffer (8 mM MgCl2, 2.5 mM TCEP,
1 mg/ml BSA, and 10% [v/v] DMSO), which included 75 mM HEPES
(pH 6.5–7.0), Tris (pH 7.0–9.0), or CHES (pH 9.0–10.0). In the
2-aminoglucosyl AGT reactions, 40 nM aAtf was used with 2 min
reaction times, while in the 6-aminoglucosyl AGT and glucosyl AGT
reactions, 5 M aAtf was used with 10 min reaction times. The
reactions were quenched and HPLC analyzed as described above.
Synthesis of Novel Lipoglycopeptides Using Gtfs and Atfs
To make compound 16 (see Figure 5A), 500 µM 6-aminoglucosyl
AGT 6, 1 mM decanoyl-CoA, and 1 µM tAtf were incubated in 100
µl of reaction buffer A (50 mM Tris [pH 9.0] and 1 mg/ml BSA) at
37°C for 60 min, generating compound 15. Two byproducts were
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140formed, the 2-O-decanoyl-6-aminoglucosyl AGT and a doubly ac-
ylated product as shown in Figure 5B. 40 l of the resulting mixture
was adjusted to a pH of 7.0 and further incubated with 500 µM
TDP-L-vancosamine and 2 µM GtfD at 37°C for 3 hr, resulting in
compound 16. To make compound 19, 500 µM 6-aminoglucosyl 1
AGT, 1 mM UDP-GlcNAc, and 5 µM tGtfA were incubated in 500 µl
of reaction buffer B (50 mM Tris [pH 7.5] and 2.5 mM TCEP) at 37°C
1for 12 hr to generate compound 17. Compound 17, purified by RP-
HPLC using a Vydac C18 small-pore column, was incubated with 1
mM decanoyl-CoA in the presence of 1 µM tAtf in 100 µl of reaction
buffer A at 37°C for 60 min, generating compound 18. Half of the
1resulting reaction mixture was incubated with 500 µM TDP-L-van-
cosamine and 2 µM GtfD at 37°C for 3 hr to produce compound
19. All reaction mixtures were analyzed by both HPLC and LCMS,
and when available, products were confirmed by coinjection with
1authentic chemically synthesized standards.
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